Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.

International journal of molecular sciences - 16 May 2018

Chien Yueh, Chou Shih-Jie, Chang Yuh-Lih, Leu Hsin-Bang, Yang Yi-Ping, Tsai Ping-Hsing, Lai Ying-Hsiu, Chen Kuan-Hsuan, Chang Wei-Chao, Sung Shih-Hsien, Yu Wen-Chung

Abstract excerpt

(1) Background: A high incidence of intervening sequence (IVS)4+919 G>A mutation with later-onset cardiac phenotype have been reported in a majority of Taiwan Fabry cohorts. Some evidence indicated that conventional biomarkers failed to predict the long-term progression and therapeutic outcome; (2) Methods: In this study, we constructed an induced pluripotent stem cell (iPSC)-based platform from Fabry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Galactosidase
Share to Arachidonate 12-Lipoxygenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arachidonate 15-Lipoxygenase

Share to Cellular Reprogramming

Share to Enzyme Replacement Therapy

Share to Nanog Homeobox Protein

Share to Octamer Transcription Factor-3

Share to SOXB1 Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 29772700
DOI: 10.3390/ijms19051480
PMCID: PMC5983630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.PMID 29772700Read ↗

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.Semantic proximity Read ↗

Fabry disease cardiomyopathy: A state-of-the-art review.Semantic proximity Read ↗

Nucleoside-Modified mRNA Encoding Alpha-Galactosidase A Reverses Fabry Disease Phenotypes in Human IPSC-Derived CardiomyocytesSemantic proximity Read ↗

Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.Semantic proximity Read ↗

Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey.Semantic proximity Read ↗

Challenging the Conventional Treatment Initiation Paradigm: Early Detection of Irreversible Cellular Damage in Cardiac Biopsies of Fabry Disease Before the Formation of Gb3 Inclusion BodiesSemantic proximity Read ↗

Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients with Fabry Disease and IVS4 + 919G>A GLA Mutation is Progressive with Age and Correlates with Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection FractionSemantic proximity Read ↗

Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.Semantic proximity Read ↗

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).Semantic proximity Read ↗

Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.Semantic proximity Read ↗

Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic CardiomyopathySemantic proximity Read ↗

Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.